Telix and Regeneron Announce Strategic Radiopharma Collaboration
View original at finance.yahoo.comTelix and Regeneron Announce Strategic Radiopharma Collaboration Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities
60% confidenceTelix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio
60% confidenceRegeneron's PD-1 inhibitor is a global standard of care for lung cancer
60% confidenceRegeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer
60% confidenceTargeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need
60% confidence